1. Home
  2. APLT vs IMOS Comparison

APLT vs IMOS Comparison

Compare APLT & IMOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLT
  • IMOS
  • Stock Information
  • Founded
  • APLT 2016
  • IMOS 1997
  • Country
  • APLT United States
  • IMOS Taiwan
  • Employees
  • APLT N/A
  • IMOS N/A
  • Industry
  • APLT Biotechnology: Pharmaceutical Preparations
  • IMOS Semiconductors
  • Sector
  • APLT Health Care
  • IMOS Technology
  • Exchange
  • APLT Nasdaq
  • IMOS Nasdaq
  • Market Cap
  • APLT 971.6M
  • IMOS 813.1M
  • IPO Year
  • APLT 2019
  • IMOS N/A
  • Fundamental
  • Price
  • APLT $9.90
  • IMOS $20.11
  • Analyst Decision
  • APLT Strong Buy
  • IMOS
  • Analyst Count
  • APLT 5
  • IMOS 0
  • Target Price
  • APLT $12.50
  • IMOS N/A
  • AVG Volume (30 Days)
  • APLT 1.5M
  • IMOS 17.1K
  • Earning Date
  • APLT 11-07-2024
  • IMOS 11-05-2024
  • Dividend Yield
  • APLT N/A
  • IMOS 5.55%
  • EPS Growth
  • APLT N/A
  • IMOS 7.03
  • EPS
  • APLT N/A
  • IMOS 0.07
  • Revenue
  • APLT N/A
  • IMOS $724,842,895.00
  • Revenue This Year
  • APLT N/A
  • IMOS $15.65
  • Revenue Next Year
  • APLT $3,169.03
  • IMOS $13.49
  • P/E Ratio
  • APLT N/A
  • IMOS $14.04
  • Revenue Growth
  • APLT N/A
  • IMOS 13.31
  • 52 Week Low
  • APLT $1.79
  • IMOS $19.93
  • 52 Week High
  • APLT $10.62
  • IMOS $32.19
  • Technical
  • Relative Strength Index (RSI)
  • APLT 65.53
  • IMOS 27.41
  • Support Level
  • APLT $9.44
  • IMOS $20.38
  • Resistance Level
  • APLT $10.62
  • IMOS $21.76
  • Average True Range (ATR)
  • APLT 0.57
  • IMOS 0.30
  • MACD
  • APLT 0.05
  • IMOS -0.19
  • Stochastic Oscillator
  • APLT 68.16
  • IMOS 6.99

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

About IMOS ChipMOS TECHNOLOGIES INC.

ChipMOS TECHNOLOGIES Inc is engaged in the research, development, manufacturing, and sale of high-integration and high-precision integrated circuits and related assembly and testing services. The company's segments include Testing, Assembly, Testing, and Assembly for LCD, OLED, and other Display Panel Driver Semiconductors (LCDD), Bumping, and others. The Company derives a majority of its revenue from Taiwan followed by Japan, the People's Republic of China, Singapore, and others.

Share on Social Networks: